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Abstract 
Context. QT interval duration is longer in women than in men. Sex steroid hormones have 
inconsistently been suggested to explain this difference. Implication of gonadotropins has 
never been studied.  
Objective. We here report the combined influence of sex steroid hormones and gonadotropins 
on QT interval duration in healthy subjects and patients with congenital adrenal hyperplasia 
(CAH) as a model of testosterone and progesterone overexpression.  
Design-Patients. Eighty four CAH patients (58 women) and 84 healthy subjects matched-
paired for sex and age were prospectively included. Circulating concentrations of 17-OH-
progesterone, progesterone, testosterone, estradiol, FSH and LH, were measured 
concomitantly to recording of a digitized electrocardiogram.  
Results. QTcFridericia(QTcF) was shorter in women with CAH than in control women (404±2 
msec vs. 413±2.1 msec, p≤0.001). 17-OH-progesterone, progesterone, progesterone/estradiol 
ratio and total testosterone were higher in women with CAH than in women controls (p<0.05) 
whereas FSH was lower (p≤0.05). According to multivariable analysis in all women, 
progesterone/estradiol ratio (β=-0.33) and FSH levels (β=0.34) were related to QTcF (r=0.5, 
p<0.0001) with no influence of CAH or healthy status. QTcF was not different between CAH 
(404.7±3.7 msec) or healthy men (396±2.8 msec). For men, QTcF (r=0.48, p<0.01) was 
negatively related to free testosterone (β=-0.29) and positively to FSH levels (β=0.34).  
Conclusion. Cardiac repolarization is influenced by complex interactions between sex steroid 
hormones and gonadotropins depending on gender. Our results indicate that 
progesterone/estradiol ratio, in women, testosterone, in men, and FSH, in both genders, are 
major determinants of ventricular repolarization with opposite effects on QTc interval. 
 
Keywords: electrocardiography, gonadotropins, physiology, Gonadal Steroid Hormones, 
congenital adrenal hyperplasia 
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Key Points 
 
1/ QTc duration, in contrast with what is generally considered, is not determined by only one 
sex steroid hormone level such as testosterone, progesterone or estradiol but is influenced by 
complex interactions between sex steroid hormones and gonadotropins, particularly FSH. The 
influence of FSH on ventricular repolarization is a new finding. Furthermore, there is a gender 
specificity in steroid hormones influence on ventricular repolarization.  
2/ In women, FSH is positively correlated while progesterone/estradiol ratio is negatively 
correlated to QTc interval duration. This finding underscores the potential for progesterone to 
be used in women as an anti-arrhythmic or prophylactic treatment of drug-induced or 
spontaneous “torsades de pointes” particularly in patients with congenital long QT 
syndromes. 
3/ In men, FSH is positively correlated while free testosterone is negatively correlated to QTc 
interval duration. As opposed to women, progesterone/estradiol is not associated to QTc 
duration in men. This finding highlights how peripheral hypogonadism favors QTc 
prolongation in men and underscores the importance of correcting this risk factor by 
testosterone administration in men with susceptibility to QTc prolongation and “torsades de 
pointes”. 
4/ Women affected by congenital adrenal hyperplasia have shorter QTcF intervals than healthy 
women and this appears to be related to higher progesterone and lower FSH levels. QTcF 
intervals tended to be higher in CAH men as compared to healthy men due to lower free 
testosterone levels. 
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Background 
In the healthy population, from puberty to menopause, women have longer QTc interval 
duration (QTc) than men 
[1,2]
.  This is associated with a higher risk of torsades de pointes or 
drug-induced arrhythmia
 [3-5]
. The role of sex steroid hormones on cardiac repolarization, 
mainly oestradiol, progesterone and testosterone, has been suggested for many years but is 
still a matter of debate. In men, despite discordant findings 
[6-14]
, testosterone is currently 
considered to shorten QTc. Studies evaluating the prolonging effect of estradiol on QT 
duration in women were highly controversial and are still a matter of debate 
[12,14-23].
 The 
negative correlation between testosterone level and QTc in women was not found in studies 
involving healthy or post menopausal women but was only confirmed in women with 
testosterone overexpression secondary to polycystic ovary syndrome 
[12,14,21,22,24]
. Data 
suggesting an influence of progesterone and progesterone/estradiol ratio on QTc shortening in 
women were issued from studies in healthy women evaluated at different times of their 
menstrual cycle 
[12,21,25,26] 
or from studies in post-menopausal women under hormone 
replacement therapy 
[15,17,18]
. Except for Δ4-androstenedione [16], the potential influence of 
other sex steroid hormones on QT interval duration, or even of the gonadotropins regulating 
their production, has never been studied. To further investigate these issues, we studied for the 
first time the combined influence of several sex steroid hormones and gonadotropins on QTc 
interval duration in healthy subjects and in patients with congenital adrenal hyperplasia 
(CAH) due to 21-hydroxylase deficiency. 21-hydroxylase deficiency leads to decreased 
cortisol and aldosterone production (Supplemental Figure 1). Cortisol deficiency results in the 
ACTH-induced accumulation of substrate precursors such as 17OHP and progesterone, and to 
increased secretion of adrenal androgens, especially androstenedione. Symptoms associated to 
this condition are related to salt loss in both gender and virilization in women. 
      The purpose of this work was first to determine if QTc is shorter in pre-menopausal CAH 
women with progesterone overexpression than in healthy women volunteers. Secondly, our 
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aim was to investigate the combined influence of gonadotropins and sex steroid hormones on 
duration of ventricular repolarization in both genders.  
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Methods 
Study design 
        Our work is ancillary to CARDIOHCS [NCT01807364], a multicenter prospective 
observational case-control study comparing early cardiovascular damages in adult men and 
women with congenital adrenal hyperplasia (CAH) due to 21α-hydroxylase deficiency and 
healthy controls. All patients gave written informed consent to participate and the study was 
approved by each hospital ethics committee. 
Study population  
       Eighty four subjects (58 women and 26 men) with CAH and 84 controls matched-paired 
for gender, age (±5 years) and smoking status (non-smoking, past smoking, active smoking) 
were prospectively included in CARDIOHCS study between May 2011 and August 2015. 
CAH adult subjects included were diagnosed with CAH during childhood, proven by genetic 
testing confirming a 21α-hydroxylase deficiency. Exclusion criteria for CAH and healthy 
subjects were: known history of cardiovascular disease and pregnancy. Estradiol and/or 
progesterone contraception in the previous month was an exclusion criteria in healthy subjects 
and was encouraged in CAH patients. CAH subjects were treated with hydrocortisone or 
dexamethasone and some of them also received fludrocortisone. Nineteen subjects were 
excluded from our ancillary study because they were either taking hormonal drugs that could 
interfere with QT interval duration (n=14) or were post-menopausal (n=5) (Supplemental 
Figure 2).  
Study procedures and laboratory analysis 
        CAH subjects were referred in CARDIOHCS study by three endocrinology unit (Pitié-
Salpêtrière hospital, Paris, France; Saint-Antoine Hospital, Paris, France; Bicêtre Hospital, Le 
Kremlin Bicêtre, France). CAH subjects and healthy subjects were explored at the Centre 
d’Investigation Clinique – Paris Est (CIC-1421, Pitié-Salpétrière hospital, Paris). 
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Participants had a clinical examination including past medical history and a 12-lead digitized 
electrocardiogram was recorded for 3 to 5 minutes after at least 10 minutes of rest in the 
supine position. Blood samples for the determination of serum concentrations of 17-OH 
progesterone, progesterone, testosterone, estradiol, follicle-stimulating hormone (FSH), 
luteinizing hormone (LH) were collected in a dry tube and further assayed at the immunology 
laboratory of Pitié-Salpêtrière. Estradiol, progesterone, FSH and LH plasma concentrations 
were assayed by chemiluminescence (Cobas E411 Roche), testosterone by 
chemiluminescence (Modular E 170 Roche), and 17-OH progesterone by radioimmunometry 
(KIP1409 Diasource).  
Electrocardiography acquisition and analysis 
       Electrocardiograms (ECG) were acquired with CardioPlug (CARDIONICS S.A., 
Brussels, Belgium), a digital recording device designed as recommended by the 
AHA/ACCF/HRS 2007 
[27]
. Subjects remained quietly in the supine position, eyes closed for 
a few minutes. QT interval was measured and corrected for heart rate by Fridericia’s formula 
(QTcF = QT/RR^0.33)
 [28]
. Fridericia’s methods was chosen, in accordance to ICH Guidelines 
issued from FDA (2005), because this latter correction is more accurate than Bazett’s 
correction for patients with elevated or below 60 beat per minute heart rates 
[29-30]
. QTc 
normal values were defined as a function of age and gender 
[30]
. For each subject, QT interval 
duration was assessed with a semi-automatic approach based on the representative beats 
generated from 30 consecutive seconds of good quality and extracted from the continuous 
electrocardiogram after at least 10 minutes of rest (CalECG®, AMPS, LLC, New-York)
 [31]
. 
RR interval used for QT correction was the average RR computed from individual RR 
intervals from sinus rhythm beats in the 30-second long strip. A global QT interval based on 
the 12-lead vector magnitude was automatically computed and then individually reviewed by 
a single blinded expert in QT measurement (JES) on the overlapped (superimposed) display 
of the representative waveforms (Supplemental Figure 3). This version of CalECG® used was 
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not suitable to directly measure QT dispersion but the method of square root of all squared 
leads used to compute global QT interval tended, by default, to annihilate any difference 
between the minimum versus the maximum (i.e. the "dispersion") in QT duration. 
Statistical analyses and power of the study 
      Data are described as mean ± standard deviations of the mean or median and interquartile 
range, as appropriate. Comparison of quantitative variables were analyzed by Student’s t-test, 
Mann-Whitney tests, ANOVA, Tukey’s test or Kruskal-Wallis tests, as appropriate. 
Comparison of qualitative variables were analyzed by Chi-2 test. The correlation between 
linear variables was assessed by calculating Pearson’s or Spearman’s coefficient (r), as 
appropriate. A 95% confidence interval for the correlation coefficient was calculated by 
Fisher’s method (Prism 6, GraphPad software®, San Diego, USA). Multivariable analysis 
was performed by ANCOVA (Xlstat software, Addinsoft®), Statistical significance was 
accepted for p<0.05.  
    The study had a 95% power to detect a QTcF difference of at least 10 msec between healthy 
women and the other subjects (by ANOVA, alpha risk 0.05; standard deviation of QTc in each 
subgroup=5 msec; expected QTcF mean=410 msec in healthy women and 400 msec in men 
and CAH women; considering n=25 in each subgroup).  
  In women (n: 99), the study had a power of 80 % to detect a significant correlation (with r > 
|0.28|, alpha risk 0.05, Student approximation) between each hormone and QTcF duration. 
  In men (n: 50), the study had a power of 80 % to detect a significant correlation (with r > 
|0.38|, alpha risk 0.05, student approximation) between each hormones and QTcF duration. 
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Results 
Clinical and electrocardiographic evaluations 
      The clinical and electrocardiographic characteristics of the patients included in this study 
are shown in Table 1. In total, one hundred forty nine adult subjects of whom 99 were 
premenopausal women (44 CAH and 55 healthy) and 50 men (24 CAH and 26 Healthy) were 
available for final analysis (Supplemental Figure 2). PR interval did not differ among groups 
(Table 1), QRS were longer (p<0.001) in healthy men (106.5±1.4 msec) compared to CAH 
females (99.3±1.1 msec) or healthy female (100.3±1.1 msec). QTcF was well corrected for 
heart rate (r=0.04 for RR and QTcF, p=0.6). CAH women had shorter QTcF compared to 
women controls (404±2 msec vs. 413±2.1 msec, p≤0.001) but QTcF in CAH women was not 
statistically different from that in men with CAH (404.7±3.7 msec) or healthy men (396±2.8 
msec) (Figure 1).  QTcF was not significantly different between healthy and CAH men. 
Biological evaluations 
     The results of biological evaluations in women are shown in Table 2. Compared to healthy 
women, women with CAH had higher levels of 17-OH progesterone (median and interquartile 
range: 15.7 ng/mL [4.7-54.2] vs. 1.2 ng/mL [0.7-2.1], p < 0.0001), progesterone (2.5 ng/mL 
[0.8-7.5] vs. 0.9 ng/mL [0.6-4.6], p=0.01), progesterone/estradiol ratio (39 [8.6-84.3] vs. 19.4 
[5.5-37], p=0.02) and total testosterone (0.55 ng/mL [0.18-0.94] vs. 0.32 ng/mL [0.24-0.41], p 
= 0.04). In contrast, FSH was lower in women with CAH than in women controls (5.1 UI/L 
[3.2-6.5] vs. 5.8 UI/L [4-8.1], p = 0.05).  
   The results of biological evaluations in men are shown in Table 2. Compared to healthy 
men, men with CAH had higher levels of 17-OH progesterone (16 ng/mL [5.5-42] vs. 
2 ng/mL [1.6-2.4], p < 0.0001) and progesterone levels which were not significantly different 
(respectively 1.3 [0.4-4.6] vs 0.8 [0.6-1] ng/mL). In contrast, bioavailable (2.1 ng/mL [1.2-
2.9] vs. 2.9 ng/mL [2.5-3.4], p <0.01) and free testosterone (93.5 pg/mL [51-124] vs. 122 
pg/mL [109-143], p <0.01) were lower in men with CAH than in healthy men. Of note, the 
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only patient in whom QTcF was > 450msec with T-waves notching (QTcF 454msec, Figure 1) 
was a man with CAH. He had normal serum electrolytes (K+=4.3mmol/l, Mg2+=0.77 
mmol/l) but had peripheral hypogonadism with the lowest free serum testosterone (0.7 ng/ml, 
[1.3-4.1]) and highest FSH level (11.3 ui/l, [1.5-12.4]) among all men included in this study.  
   Serum potassium and magnesium levels ranged within normal values respectively from 3.4-
4.9 mmol/l and 0.74-0.87 mmol/l in almost all CAH patients. Kalemia and serum magnesium 
were unrelated to QTcF duration (Supplemental Figure 4). Serum potassium and magnesium 
levels were not measured in healthy volunteers. 
Correlation between QTcF duration and sex hormones in women  
        According to univariable analysis in all women (Table 3, Figure 2, n=99), QTcF duration 
was negatively correlated with 17-OH progesterone (r=-0.28, p<0.01), progesterone (r=-0.29, 
p<0.01), progesterone/estradiol ratio (r= -0.38, p<0.001), total testosterone (r=-0.2, p<0.01)  
and positively correlated with FSH (r= 0.38, p<0.001) and LH (r= 0.3, p < 0.01). There was 
no significant correlation between QTcF and estradiol in women.  
      Multivariable analysis (ANCOVA) was performed in all women to overcome significant 
autocorrelations between sex hormones and gonadotropins (Supplemental Table 1).  This 
multivariable analysis showed that progesterone/estradiol ratio (β=-0.33, p<0.001) and FSH 
levels (β=0.35, p<0.001) were independently related to QTcF (r=0.5, p<0.0001) without 
influence of CAH or healthy status.  
Correlation between QTcF duration and sex hormones in men  
        According to univariable analysis in all men (Table 3, Figure 3, n=50), QTcF duration 
was negatively correlated with free testosterone (r=-0.34, p=0.01), and positively correlated to 
FSH (r= 0.39, p<0.01). There was no significant correlation between QTcF and progesterone 
or estradiol in men.  
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      According to multivariable analysis (ANCOVA) in all men free testosterone (β=-0.27, 
p<0.05) and FSH levels (β=0.4, p<0.01) were independently related to QTcF (r=0.49, p 0.001) 
with no influence of CAH or healthy status.  
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Discussion 
   The objective of this work was to investigate the influence of complex interactions between 
gonadotropins and several sex steroid hormones on the duration of ventricular repolarization 
in humans, depending on gender. We found that: 1/ CAH women with high progesterone and 
low FSH levels, have shorter QTcF intervals than healthy women; 2/ in women, FSH is 
positively correlated while progesterone/estradiol ratio is negatively correlated to QTcF 
interval duration; 3/ in men, FSH is positively while free testosterone is negatively correlated 
to QTcF interval duration. These findings support the hypothesis of a regulation of QT 
interval duration not by a single sex hormone as previously suggested, but by an integrated 
complex hormonal system depending on gender, gonadotropins and peripheral sex steroid 
hormones. Our results indicate that progesterone/estradiol ratio, in women, testosterone, in 
men, and FSH, in both genders, are major determinants of ventricular repolarization with 
opposite effects on QTc interval. 
Rationale for a complex hormonal system regulating QTcF 
   Previous studies evaluating the role of sexual hormones on QTcF duration only evaluated 
the isolated role of testosterone, progesterone and estradiol and did not assess the 
multivariable influence of complex interactions between several sex hormones and 
gonadotropins. Sex steroid hormones secretions are constantly regulated by the hypothalamic-
pituitary axis and, as occurs in other organs such as ovaries, testes or bone
 [32]
, the influence of 
sex steroid hormones on QT interval duration may be counterbalanced by the direct effects of 
gonadotropins. The rationale for a complex hormonal system regulating QTcF is supported by 
the fact that RNA of gonadotropins receptors are expressed in the myocardium
 [33]
. Our study 
including post-puberty healthy subjects, and CAH patients overexpressing progesterone and 
testosterone in women is unique, in that subjects were exposed to a wide range of sex steroid 
hormones and gonadotropins levels.  
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Influence of sex steroid hormones on QTcF in men and women 
    The mechanisms underlying the difference between QTc interval duration in men and 
women are poorly understood. Differences in gonadic steroid hormones expression cannot 
fully explain this difference and non-gonadal, gender-specific, mechanisms involving 
ventricular ion channel expression or modulation have been demonstrated in non-clinical 
models 
[14,34-35]
. Our results support the hypothesis that testosterone is the main steroid 
hormone modulating QTc in men while QTc is influenced by serum progesterone or 
progesterone/estradiol ratio in women. Interestingly, other studies have emphasized the 
influence of testosterone on QTc in men
 [11-14]
 and of progesterone (more than estradiol) in 
women
 [21]
. Furthermore, in non-clinical models, testosterone and progesterone have been 
shown to shorten ventricular action potential duration while estradiol was associated with 
action potential prolongation
 [34-39]
. As a consequence, CAH women expressing higher 
progesterone levels than healthy subjects had a shorter QTcF than control women, therefore 
reaching QTcF duration observed in CAH men. Of note, Annekin et al have recently reported 
a QTc shortening in women after clominophen administration despite an important estradiol 
release
 [40]
. Clomiphene, as a fertility inducer exert an anti-estradiol effect on pituitary axis 
and might have also anti-estradiol properties on heart repolarization. Thus, the negative 
correlation found between estradiol and QTc post-clomiphene administration had to be 
interpreted with great caution. 
Role of FSH on QTcF interval duration 
     To our knowledge, this is the first study assessing the potential influence of gonadotropins 
on QTcF duration. Our findings add new insight to the understanding of the observed 
differential regulation of QTc interval in healthy women compared to healthy men. They 
indicate that it results, at least in part, from the combined higher gonadotrophin levels in 
women and higher testosterone levels in men. Despite significant autocorrelations between 
FSH and LH, our multivariable analysis supports a major role of FSH in regulating QTc 
 14 
interval duration.  Interestingly, Turner syndrome, a congenital condition associated with 
ovarian steroid hormones deficit counterbalanced by high FSH concentrations, is associated 
with QTcF prolongation
 [41]
. In premenopausal women, bilateral oophorectomy followed by 
FSH increment was associated with prolongation of T wave duration. Estradiol administration 
in these women decreased FSH level and corrected T wave duration
 [20]
. In hypogonadotropic 
hypogonadic men (low FSH level), there was no difference in QTc compared to healthy 
control
 [7]
. Men with peripheral hypogonadism, presenting low testosterone concentrations and 
high FSH concentrations, had longer QTc compared to healthy men
 [11]
. Finally, patients with 
polycystic ovary syndrome in whom there is QTcF shortening
 [22]
 have an increase in 
testosterone levels but also an increase in LH/FSH ratio with relatively low FSH levels 
compared to LH
 [11,42]
.   
Perspectives 
   The lengthening effect of FSH on QTc is a new finding that should be confirmed. Polycystic 
ovary syndrome patients may require recombinant FSH administration to improve their 
fertility
 [42]
. It would be worth evaluating if the short QTc found in this disease
 [22]
 is corrected 
by FSH administration. One could also test if subjects with FSHR polymorphisms 
[43]
 leading 
to either hyperactivated or inactive FSH receptor have longer or shorter QTc intervals, 
respectively, than carriers of the wild FSHR gene.  
   The results of our study suggest a protective effect of progesterone administration on QT 
lengthening in women. Progesterone has already been successfully used to prevent induction 
of ventricular arrhythmia in a rabbit model of congenital long QT syndrome
 [44]
. Further 
investigations are needed to confirm if progesterone can prevent or even cure drug-induced 
torsades de pointes by shortening QTc duration specifically in women. New non-clinical 
models using human cardiomyocytes derived from induced pluri-potent stem cells of normal 
or long QT syndrome patients could be used for this purpose
 [45,46]
. We believe our results may 
lead to new developments in the field of anti-arrhythmic drugs, particularly concerning use of 
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exogenous hormonal administration. A blinded randomized trial evaluating drug-induced QTc 
interval changes
 [21]
 in women taking different progestin-derived pill with different androgenic 
power or a placebo could be performed to evaluate if those different strategies lead to 
differential QTc lengthening.  
 
Limitations 
    In our study, we found only moderate correlations between individual sex hormones and 
QTc. This issue raises the question of whether the effect of sex hormones on ion channels and 
cardiac repolarization is direct or indirect. Several non-clinical studies indicate that sex steroid 
hormones may lead to a transcriptional, post-transcriptional or post-translational effect on ion 
channels expression and regulation more than a direct channel on/off effect
 [37-40]
.  
   The analysis of QTcF interval duration in the present study relies on gender and sex 
hormones plasma levels. This analysis could be improved by adding other parameters known 
to influence QTc interval duration such as kalemia and plasma aldosterone 
[47]
 or information 
about genetic polymorphisms or mutations associated with QTc prolongation 
[48]
. Thus, 
kalemia imbalance alters QTc duration in very abnormal situation such as severe hypokalemia 
when fusion between T and U wave might contribute artificially to QTc prolongation 
[49]
. No 
subjects included in this study presented U wave and kalemia was lacking only in healthy 
volunteers for whom kalemia is expected to be within normal range. 
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Conclusion 
    Cardiac repolarization is influenced by complex interactions between sex steroid hormones 
and gonadotropins depending on gender. Our results indicate that progesterone/estradiol ratio, 
in women, testosterone, in men, and FSH, in both genders, are major determinants of 
ventricular repolarization with opposite effects on QTc interval. 
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Figures legends 
 
Figure 1. QTcF interval duration in healthy men, healthy women, and subjects with 
congenital adrenal hyperplasia (CAH) 
Statistics: p values are given by one-way ANOVA with post-hoc Tukey’s test. The black line 
represent the mean and the error bars in black represent the standard error of the mean. 
 
Figure 2. Correlations between levels of progesterone (A), estradiol (B), 
progesterone/estradiol ratio (C), free testosterone (D), FSH (E), LH (F) and QTcF in all 
women (n=99). 
 
Figure 3. Correlations between levels of progesterone (A), estradiol (B), 
progesterone/estradiol ratio (C), free testosterone (D), FSH (E), LH (F) and QTcF in all 
men (n=50). 
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Tables 
 
Table 1: Clinical and electrographic characteristics of the patients included in the study 
 
 
Abbreviations: bpm: beats per minute; CAH: Congenital adrenal hyperplasia; cm: 
centimeter; kg: kilograms; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: 
heart rate; msec: millisecond  
Statistics: ANOVA test for quantitative variables and Chi2 for qualitative variables. Not 
significant (ns) if p > 0.05. Quantitative variables are represented by the mean +/- the 
standard deviation of the means. * Significant compared to healthy females; † Significant 
compared to CAH females; ‡ Significant compared to healthy males; § Significant compared 
to CAH males. 
 CAH 
males 
Healthy 
males 
CAH 
females 
Healthy 
females 
p 
Number of subjects 24 26 44 55  
Age (years) 29.1±1.7 28.6±1.7 30.2±1.3 29.8±1 ns 
Height (cm) 170.1±1.3
†‡
 180.3±1.3
*†§
 157.9±1.1
*‡§
 166.7±0.9
†‡
 <0.0001 
Weight (kg) 74.9±2.8
*†
 76.3±2.2
*†§
 63.5±1.8
‡
 66.1±1.3
‡§
 <0.0001 
Sedentary (%) 9 (37%) 7 (27%) 16 (37%) 13 (24%) ns 
Cardiovascular 
disease in family (%) 
 
0 (0%) 
 
1 (4%)  
 
1 (2%) 
 
5 (9%) 
ns 
SBP (mmHg) 117.3±2
†
 118.9±1.7
*†
 107.5±1.8
‡§
 108.1±1.4
‡
 <0.0001 
DBP (mmHg) 69.1±2 69.6±1.43 67.6±1.8 68.3±1.1 ns 
PR (msec) 155.3±5.3 158.5±5.1 149.1±2.7 154.3±3.7 ns 
QRS (msec) 106.4±2.5 106.5±1.4
*†
 99.3±1.1
‡
 100.3±1.1
‡
 < 0.001 
QT (msec) 397.6±5 393.5±4.3 385.2±4
*
 402±3.7
†
 <0.05 
RR (msec) 955.3±30.7 983.6±21.5
†
 872.4±20.9
‡
 917.2±20.7 <0.01 
HR (bpm) 64.3±2.1 61.7±1.3
†
 70.4±1.6
‡
 67.1±1.4 <0.01 
QTcF (msec) 406±4.8 396.5±2.8
*
 403.4±2.1
*
 412.8±2.1
†‡
 < 0.001 
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Table 2: Biological evaluations in females and males 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: FSH: follicle stimulating hormone; LH: luteinizing hormone; SHBG: Sex 
hormone-binding globulin; ACTH: Adrenocorticotropic hormone 
Statistics: Mann-Whitney test for quantitative variables. Quantitative variables are 
represented by the median and the interquartile interval Not significant (ns) if p > 0.05. 
Significant results are in bold. 
 FEMALES  
 CAH females 
n: 44 
Healthy females 
n: 55 
p 
17-OH progesterone (ng/mL) 15.7 [4.7-54.2] 1.2 [0.7-2.1] < 0.0001 
Progesterone (ng/mL) 2.5 [0.8-7.5] 0.9 [0.6-4.6] 0.01 
Bioavailable testosterone (ng/mL) 0.13 [0.04-0.3] 0.08 [0.04-0.14] 0.09 
Free testosterone (pg/mL) 5.9 [1.7-14] 3.7 [1.9-6.3] ns 
Total testosterone (ng/mL) 0.55 [0.18-0.94] 0.32 [0.24-0.41] 0.04 
Estradiol (pg/mL) 71 [44 -171.5] 93 [46-171] ns  
FSH (UI/L) 5 [3.2-6.5] 5.8 [4-8.1] 0.05 
LH (UI/L) 5.6 [3.2-8.8] 6.3 [5.1-10.6] 0.07  
Progesterone/Estradiol  39 [8.6-84.3] 19.4 [5.5-37] 0.02 
  MALES 
 CAH males 
n: 24 
Healthy males 
n: 26 
p 
17-OH progesterone (ng/mL) 16 [5.5-42] 2 [1.6-2.4] < 0.0001 
Progesterone (ng/mL) 1.3 [0.4-4.6] 0.8 [0.6-1] ns 
Bioavailable testosterone (ng/mL) 2.1 [1.2-2.9] 2.9 [2.5-3.4] <0.01 
Free testosterone (pg/mL) 93.5 [51-124] 122 [109-143] <0.01 
Total testosterone (ng/mL) 4.6 [3.1-6.6] 5.9 [4.9-6.6] ns 
Estradiol (pg/mL) 27.9 [19.3-32.4] 28.3 [24.7-37.3] ns 
FSH (UI/L) 3.5 [2.3-6.5] 3.4 [2.6-5.2] ns 
LH (UI/L) 4.5 [1.9-5.6] 4.5 [3.5-5.3] ns  
Progesterone/Estradiol 5.1 [1.5-12.4] 2.6 [1.5-3.1] 0.03 
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Table 3: Correlation between QTcFridericia and sex hormone or gonadotropins in men 
and women 
  
 
 Female (n: 99) Male (n: 50) 
17-OH progesterone 
(ng/mL) 
r: -0.28 [-0.08;-0.45] 
p <0.01 
r: 0.07 
ns 
Progesterone  
(ng/mL) 
r: -0.29 [-0.1; -0.46] 
p <0.01 
r: -0.02  
ns 
Estradiol  
(pg/mL) 
r: -0.02  
ns 
r: 0.01  
ns  
Progesterone/Estradiol 
(Ratio) 
r:-0.38 [-0.2; -0.54] 
p <0.001 
r: -0.02 
ns 
Bioavailable 
testosterone (pg/mL) 
r:-0.25 [-0.05; -0.43]    
p 0.01  
r: -0.32 [-0.04; -0.55] 
p 0.03 
Free testosterone 
(ng/mL) 
r: -0.2   
ns 
r: -0.34 [-0.07; -0.57]   
p 0.01 
Total testosterone 
(ng/mL) 
r: -0.26[-0.07; -0.44]   
p <0.01 
r: - 0.16 
ns 
FSH  
(UI/L) 
r: 0.38 [0.2; 0.54] 
p <0.001 
r: 0.39 [0.12; 0.6] 
p  <0.01 
LH  
(UI/L) 
r: 0.3 [0.1; 0.47] 
p <0.01  
r: 0.02  
ns 
 
Abbreviations: FSH: follicle stimulating hormone; LH: luteinizing hormone; NA: Not 
applicable; SHBG: Sex hormone-binding globulin 
Statistics: Correlations were assessed within female and male subgroups by Spearman’s or 
Pearson’s coefficient (r) with its 95% confidence interval [;] when significant. A 95% 
confidence interval for the correlation coefficient was calculated by Fisher’s method. Not 
significant (ns) if p > 0.05. Significant results are in bold.  
     
 
 
